Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: A randomized, placebo-controlled, multicenter trial for one to three years

Journal of Clinical Endocrinology and Metabolism

Volumn 93, Issue 3, 2008, Pages 823-831

  Mauras, Nelly ^a   De Pijem, Lilliam Gonzalez ^d   Hsiang, Helen Y ^b   Desrosiers, Paul ^c   Rapaport, Robert ^e   Schwartz, I David ^f   Klein, Karen Oerter ^g   Singh, Ravinder J ⁱ   Miyamoto, Anna ^h   Bishop, Kim ^a  

^a NEMOURS CHILDREN S CLINIC   (United States)

^b Children's Clinic   (United States)

^c NEMOURS CHILDREN S HOSPITAL   (United States)

^d UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^e MOUNT SINAI MEDICAL CENTER   (United States)

^f UNIVERSITY OF SOUTH CAROLINA   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h ASTRAZENECA   (United Kingdom)

ⁱ MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ESTRADIOL; ESTRONE; GLUCOSE; GROWTH HORMONE; HUMAN GROWTH HORMONE; PLACEBO; TESTOSTERONE;

ARTICLE; BODY COMPOSITION; BODY HEIGHT; BONE AGE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GASTROINTESTINAL DISEASE; GROWTH HORMONE DEFICIENCY; HEAD AND NECK DISEASE; HOSPITAL DISCHARGE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; PRIORITY JOURNAL; PUBERTY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; UROGENITAL TRACT DISEASE; VIRILIZATION; VOMITING;

EID: 40849085155     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-1559     Document Type: Article

References (49)

1. Mauras N, Attie KM, Reiter EO, Saenger P, Baptista J 2000 High dose recombinant human growth hormone (GH) treatment of GH-deficient patients in puberty increases near-final height: a randomized, multicenter trial. J Clin Endocrinol Metab 85:3653-3660
2. Mericq MV, Eggers M, Avila A, Cutler Jr GB, Cassorla F 2000 Near final height in pubertal growth hormone (GH)-deficient patients treated with GH alone or in combination with luteinizing hormone- releasing hormone analog: results of a prospective, randomized trial. J Clin Endocrinol Metab 85:569-573
3. Cassorla F, Mericq V, Eggers M, Avila A, Garcia C, Fuentes A, Rose SR, Cutler GB 1997 Effects of luteinizing hormone-releasing hormone analog-induced pubertal delay in growth hormone (GH)-deficient children treated with GH: preliminary results. J Clin Endocrinol Metab 82:3989-3992
4. Cara JF, Kreiter ML, Rosenfield RL 1992 Height prognosis of children with true precocious puberty and growth hormone deficiency: effect of combination therapy with gonadotropin releasing hormone agonist and growth hormone. J Pediatr 120:709-715
5. Reiter EO 2006 A brief review of the addition of gonadotropin-releasing hormone agonists (GnRH-Ag) to growth hormone (GH) treatment of children with idiopathic growth hormone deficiency: previously published studies from America. Mol Cell Endocrinol 254-255:221-225
6. Pasquino AM, Pucarelli I, Roggini M, Segni M 2000 Adult height in short normal girls treated with gonadotropin-releasing hormone analogs and growth hormone. J Clin Endocrinol Metab 85:619-622
7. Balducci R, Toscano V, Mangiantini A, Municchi G, Vaccaro F, Picone S, Di Rito A, Boscherini B 1995 Adult height in short normal adolescent girls treated with GnRHa and GH. J Clin Endocrinol Metab 80:3596-3600
8. Lanes R, Gunczler P 1998 Final height after combined growth hormone and gonadotropin-releasing hormone analogue therapy in short healthy children entering into normally timed puberty. Clin Endocrinol (Oxf) 49:197-202
9. Smith EP, Boyd J, Frank GR 1994 Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 331:1056-1061
10. Carani C, Qin K, Simoni M 1997 Effect of testosterone and estradiol in man with aromatase deficiency. N Engl J Med 1337:91-95
11. Morishima A, Grumbach MM, Simpson ER, Fisher C, Qin K 1995 Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens. J Clin Endocrinol Metab 80:3689-3698
12. Gunther DF, Calikoglu AS, Underwood LE 2000 The effects of the estrogen receptor blocker, Faslodex (ICI 182,780), on estrogen-accelerated bone maturation in mice. Pediatr Res 46:269-273
13. Mauras N, O'Brien KO, Klein KO, Hayes V 2000 Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 85:2370-2377
14. Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ 1998 Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength and adiposity. J Clin Endocrinol Metab 83:1886-1892
15. Mauras N, Hayes V, Yergey AL 1999 Profound hypogonadism has significant negative effects on calcium balance in males: a calcium kinetic study. J Bone Miner Res 14:577-582
16. Wickman S, Sipila I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L 2001 A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomized controlled trial. Lancet 357:1743-1748
17. Hero M, Norjavaara E, Dunkel L 2005 Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial. J Clin Endocrinol Metab 90:6396-6402
18. Nelson RE, Grebe SK, OKane DJ, Singh RJ 2004 Liquid chromatography-tandem mass spectrometry assay for simultaneous measurement of estradiol and estrone in human plasma. Clin Chem 50:373-384
19. Greulich WW, Pyle SI 1959 Radiographic atlas of skeletal development of the hand and wrist. Stanford, CA: Stanford University Press
20. Durnin JV, Womersley J 1974 Body fat assessed from total body density and its estimation from skinfold thickness: measurements on 481 men and women aged from 16 to 72 years. Br J Nutr 32:77-97
21. Steinberger J, Jacobs DR, Raatz S, Moran A, Hong CP, Sinaiko AR 2005 Comparison of body fatness measurements by BMI and skinfolds vs dual energy x-ray absorptiometry and their relation to cardiovascular risk factors in adolescents. Int J Obes (Lond) 29:1346-1352
22. Ibáñez L, Valls C, Ong K, Dunger DB, de Zegher F 2006 Metformin therapy during puberty delays menarche, prolongs pubertal growth, and augments adult height: a randomized study in low-birth-weight girls with early-normal onset of puberty. J Clin Endocrinol Metab 91:2068-2073
23. Zachmann M, Sobradillo B, Frank M, Frisch H, Prader A 1978 Bayley-Pinneau, Roche-Wainer-Thissen, and Tanner height predictions in normal children and in patients with various pathologic conditions. J Pediatr 93:749-755
24. Bramswig JH, Fasse M, Holthoff ML, von Lengerke HJ, von Petrykowski W, Schellong G 1990 Adult height in boys and girls with untreated short stature and constitutional delay of growth and puberty: accuracy of five different methods of height prediction. J Pediatr 117:886-891
25. Joss EE, Temperli R, Mullis PE 1992 Adult height in constitutionally tall stature: accuracy of five different height prediction methods. Arch Dis Child 67:1357-1362
26. de Waal WJ, Greyn-Fokker MH, Stijnen T, van Gurp EA, Toolens AM, de Munick Keizer-Schrama SM, Aarsen RS, Drop SL 1996 Accuracy of final height prediction and effect of growth-reductive therapy in 362 constitutionally tall children. J Clin Endocrinol Metab 81:1206-1216
27. Bull RK, Edwards PD, Kemp PM, Fry S, Hughes IA 1999 Bone age assessment: a large scale comparison of the Greulich and Pyle, and Tanner and Whitehouse (TW2) methods. Arch Dis Child 81:172-173
28. Hintz RL 2001 Final height prediction in constitutional growth delay. J Pediatr Endocrinol Metab 14 (Suppl 6):1535-1540
29. Ranke MB, Lindberg A, Martin DD, Bakker B, Wilton P, Albertsson-Wikland K, Cowell CT, Price DA, Reiter EO 2003 The mathematical model for total pubertal growth in idiopathic growth hormone (GH) deficiency suggests a moderate role of GH dose. J Clin Endocrinol Metab 88:4748-4753
30. Mauras N, Welch S, Rini A, Klein KO 2004 An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys. J Pediatr Endocrinol Metab 17:1597-1606
31. Klein KO, Baron J, Colli MJ, McDonell DP, Cutler GB 1994 Estrogen levels in childhood determined by an ultrasensitive recombinant cell bioassay. J Clin Invest 94:2475-2480
32. Plourde P, Dyroff M, Dukes M 1994 Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Res Treat 30:103-111
33. Plourde P, Dyroff M, Dowsett M, Demers L, Yates R, Webster A 1995 Arimidex: a new oral, once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 53:175-179
34. Mauras N, Haymond H 2005 Are the metabolic effects of GH and IGF-I separable? Growth Horm IGF Res 15:19-27
35. Baroncelli GI, Bertelloni S, Ceccarelli C, Saggese G 1998 Measurement of volumetric bone mineral density accurately determines degree of lumbar undermineralization in children with growth hormone deficiency. J Clin Endocrinol Metab 83:3150-3154
36. Hogler W, Briody J, Moore B, Lu PW, Cowell CT 2005 Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency. Bone 37:642-650
37. Fewtrell MS, Gordon I, Biassoni L, Cole TJ 2005 Dual x-ray absorptiometry (DXA) of the lumbar spine in a clinical paediatric setting: does the method of size-adjustment matter? Bone 37:413-419
38. Lewiecki EM, Binkley N, Bilezikian JP, Kendler DL, Leib ES, Petak SM 2006 Official positions of the International Society for Clinical Densitometry. Osteoporos Int 17:1700-1701
39. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML; Endocrine Society's Clinical Guidelines Subcommittee, Stephens PA 2006 Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 91:1621-1634
40. Rosenfeld RG, Albertsson-Wikland K, Cassorla F, Frasier SD, Hasegawa Y, Hintz RL, Lafranchi S, Lippe B, Loriaux L, Melmed S, Preece MA, Ranke MB, Reiter EO, Rogol AD, Underwood LE, Werther GA 1995 Diagnostic controversy: the diagnosis of childhood growth hormone deficiency revisited. J Clin Endocrinol Metab 80:1532-1540
41. Hilczer M, Smyczynska J, Stawerska R, Lewinski A 2006 Stability of IGF-I concentration despite divergent results of repeated GH stimulating tests indicates poor reproducibility of test results. Endocr Regul 40:37-45
42. Anckaert E, Schiettecatte J, Vanbesien J, Smitz J, Velkeniers B, De Schepper J 2006 Variability among five different commercial IGF-1 immunoassays in conditions of childhood-onset GH deficiency and GH therapy. Acta Clin Belg 61:335-339
43. Casper RF, Mitwally MFM 2006 Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab 91:760-771
44. Raman JD, Schlegel PN 2002 Aromatase inhibitors for male infertility. J Urol 167:624-629
45. Reiter EO, Norjavaara E 2005 Testotoxicosis: current viewpoint. Pediatr Endocrinol Rev 3:77-86
46. Kreher NC, Pescovits OH, Delameter P, Tiulpakov A, Hochberg Z 2006 Treatment of familial male-limited precocious puberty with bicalutamide and anastrozole. J Pediatr 149:416-420
47. Karmazin A, Moore WV, Popovic J, Jacobson JD 2005 The effect of letrozole on bone age progression, predicted adult height, and adrenal gland function. J Pediatr Endocrinol 18:285-293
48. Mauras N, Lima J, Patel D, Rini A, DiSalle E, Kwok A, Lippe B 2003 A pharmacokinetics and dose finding of a potent aromatase inhibitor, Aromasinâ (Exemestane) in young males. J Clin Endocrinol 88:5951-5956
49. Hero M, Wickman S, Dunkel L 2006 Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty. Clin Endocrinol (Oxf) 64:510-513